What Celecoxib Pentafarma Treats: Main Uses and Benefits

Celecoxib Pentafarma is used across therapeutic domains where additional symptomatic support is needed to ease the overall burden of symptoms related to inflammatory or irritative states and physical discomfort. The medication is considered relevant in clinical settings that involve acute or unstable symptom patterns.

This medicine is commonly used to help with conditions presenting with systemic or localized discomfort. Specifically, it plays a role in managing the persistent symptoms of chronic inflammatory arthropathies such as osteoarthritis (OA), rheumatoid arthritis (RA), and ankylosing spondylitis (AS). It is also applied in addressing acute pain and symptoms that become more disruptive during flare-ups like primary dysmenorrhea (menstrual cramps).

By managing the persistent symptoms that interfere with daily functioning, such as joint pain, tenderness, and stiffness, the medication may assist with maintaining functional stability and helps improve day-to-day comfort during symptomatic periods. It is also applied in addressing symptoms related to Juvenile Rheumatoid Arthritis (JIA) in children and may be part of symptomatic management for polyps in Familial Adenomatous Polyposis (FAP).

---

Quick Fact: Relief for Stiffness and Swelling

Celecoxib is relevant for easing symptoms related to inflammatory or irritative states such as swelling and localized heat, providing supportive relief when symptoms interfere with routine activities.

Regulatory References

1. NIH MedlinePlus overview of Celecoxib uses

Who can and cannot use Celecoxib Pentafarma?

The official eligibility profile for celecoxib is strictly defined by regulatory bodies, outlining populations for whom use is allowed, restricted, or absolutely prohibited.

Contraindicated Populations: Use of the medicine is prohibited for patients with known hypersensitivity to celecoxib, any component of the medicine, or to sulfonamides (sulfa allergy). It is also strictly contraindicated for those with a history of allergic reactions (like asthma or hives) after taking aspirin or other NSAIDs, and for pain management following Coronary Artery Bypass Graft (CABG) surgery. Absolute non-eligibility applies to patients with severe hepatic impairment (Child-Pugh Class C) or severe renal insufficiency (estimated creatinine clearance less than 30 mL/min).

Age and Life Stage: The medicine is established for adults. Pediatric use is only approved for Juvenile Rheumatoid Arthritis in children two years of age and older; safety is not established for children younger than two years. The medicine is contraindicated during the third trimester of pregnancy (starting at 30 weeks gestation).

Restrictions and Caution: Use requires dose reduction in patients with moderate hepatic impairment (Child-Pugh Class B) and in individuals identified as CYP2C9 Poor Metabolizers. Dehydration or hypovolemia must be corrected prior to treatment initiation.

Interactions with other medicines and products

The regulatory interaction profile for Celecoxib Pentafarma is defined by metabolic and pharmacodynamic constraints. Concomitant use with non-aspirin Nonsteroidal Anti-inflammatory Drugs (NSAIDs) is officially noted to increase the risk of serious gastrointestinal complications and should be avoided. The medicine is also formally contraindicated for the management of peri-operative pain in the Coronary Artery Bypass Graft (CABG) surgery setting.

Pharmacodynamically, co-administration with oral anticoagulants (e.g., Warfarin) is associated with an increased risk of serious bleeding events and necessitates close monitoring of anticoagulant activity. Celecoxib may also diminish the antihypertensive effect of ACE Inhibitors and ARBs, which carries a specific warning regarding deterioration of renal function in high-risk populations, such as the elderly.

The medicine interacts with the Cytochrome P450 enzyme system. Strong CYP2C9 inhibitors (e.g., Fluconazole) increase Celecoxib plasma concentrations due to reduced metabolic clearance. Conversely, Celecoxib is documented to inhibit CYP2D6, which leads to increased plasma levels of co-administered CYP2D6 substrate medicines. Furthermore, the serum concentrations of substances like Lithium and Digoxin are formally noted to be increased when co-administered.

The mechanism of Celecoxib is fundamentally rooted in its highly selective action on an enzyme system critical for the synthesis of inflammatory mediators. It acts within domains that modulate physiological processes at the site of cellular distress.

Selective Targeting of the COX-2 Enzyme System

The drug engages mechanisms that influence key regulatory systems by acting as a selective inhibitor of the enzyme Cyclooxygenase-2 ( COX-2). This enzyme is chiefly responsible for the accelerated production of signaling molecules during periods of cellular activation. This mechanism modulates the influence of excessive mediator activity, contributing to pathway stabilization within the targeted pathways.

Suppression of Prostaglandin Synthesis

The selective inhibition initiates or suppresses signaling sequences by blocking the conversion of the precursor molecule, arachidonic acid, into prostaglandins ( PGE2). By modifying these early molecular steps, the drug dampens the cascade that leads to the peripheral sensitization of nociceptors and localized vascular changes.

Preservation of Homeostatic COX-1 Functions

Celecoxib is associated with modulation across key mechanistic domains because its high selectivity means it largely spares the constitutive COX-1 enzyme, which maintains essential baseline functions, particularly the integrity of the gastrointestinal mucosal lining. This targeted pathway adjustment contributes to pathway stabilization within key physiological processes, resulting in specific physiological modulations that define the drug's effect profile.

How to Use Celecoxib Pentafarma

Celecoxib Pentafarma is designated for oral administration, typically provided as a hard gelatine capsule. Usage is strictly governed by the official dose and frequency schedules to ensure the lowest effective dose is used for the shortest duration.

---

Standard Labeled Dosing Regimens

Condition	Standard Dose Regimen	Maximum Daily Dose
Osteoarthritis (OA)	200 mg once daily (QD) or 100 mg twice daily (BID)	400 mg
Rheumatoid Arthritis (RA)	100 mg to 200 mg twice daily (BID)	400 mg
Ankylosing Spondylitis (AS)	200 mg QD or in two divided doses	400 mg
Acute Pain	400 mg initial, followed by 200 mg BID as needed	600 mg (Day 1)

---

Administration and Special Conditions

The medicine can generally be administered without regard to the timing of meals for doses up to 200 mg twice daily. If a patient is unable to swallow the capsule, the contents may be emptied onto a level teaspoon of specific cool or room temperature soft foods—such as applesauce, rice gruel, yogurt, or mashed banana—and must be ingested immediately with water; the contents are not to be crushed or chewed.

In cases of moderate hepatic impairment (Child-Pugh Class B), the maximum daily dose must be reduced by 50%. Similarly, a dose reduction to half the lowest recommended dose may be considered for individuals identified as CYP2C9 poor metabolizers. If a dose is missed, it should be skipped, and the patient should resume the next scheduled dose, as it is advised not to double doses to compensate.

Research Evidence / Overview of Studies

---

Evaluating Use in Neuropathic Pain

Research has explored the role of Celecoxib Pentafarma (celecoxib) in managing chronic neuropathic pain. Studies have examined whether the drug modulates the time course and intensity of symptoms. These investigations included a range of participant groups, with varied causes of nerve-related discomfort.

Investigators recorded outcomes related to reports of persistent discomfort. The primary focus was on reported changes in pain severity and how these changes were maintained over the study period. Studies evaluated changes in pain scores over periods up to 12 weeks.

Study Profiles and Participant Characteristics

Studies examining the drug's profile assessed various dosing regimens. The majority of the studies involved adult participants, typically lasting between 4 and 12 weeks.

Research explored the drug's profile in individuals who had experienced difficulties with standard treatments. This research provided descriptive data regarding the tolerability profile in participants who had difficulties with prior treatments.

Some research has investigated the effects of the drug when used concurrently with physiotherapy. These observational studies aimed to describe outcomes for individuals receiving this combined approach.

Safety and Side Effects Profile

Clinical trials included assessments and reports of adverse events in adult participants. In these trials, the most commonly reported events included dizziness, fatigue, and dry mouth. These trials included monitoring for specific adverse effects.

Researchers assessed the drug's profile in participants with pre-existing conditions, including liver conditions. These studies described aspects of the drug's metabolism and elimination in these specific populations. It is not yet clear whether the drug presents a different risk profile for these individuals compared to the general study population.

Future Research

Data from the studies do not currently extend to the drug's effects beyond the 12-week period studied. Future research continues to investigate its longer-term profile and observed effects.

Common questions about Celecoxib Pentafarma (FAQ)

---

Q: Is Celecoxib Pentafarma different from other common NSAIDs like ibuprofen or naproxen?

Official product information describes this medicine as a selective COX-2 inhibitor. This indicates its primary action targets the Cyclooxygenase-2 enzyme, which is associated with pain and inflammation. Unlike older, non-selective NSAIDs, it largely spares the COX-1 enzyme, which helps maintain the protective lining of the stomach and other baseline functions.

---

Q: How long can a person safely continue to use Celecoxib Pentafarma?

Regulatory agencies advise using the lowest effective dose for the shortest duration necessary to control symptoms. For chronic conditions like certain types of arthritis, the need for continued use should be periodically re-evaluated by a healthcare professional to ensure treatment remains appropriate.

---

Q: Can Celecoxib Pentafarma be used for short-term pain, such as menstrual cramps?

Yes, the official indications for the medicine include the management of Primary Dysmenorrhea, which is the medical term for menstrual cramps, in adults. It is also approved for other forms of acute, short-term pain.

---

Q: What symptoms should prompt a person to stop taking Celecoxib Pentafarma immediately?

If serious symptoms occur, official guidance indicates that discontinuation is required immediately. These include the first sign of a skin rash, mucosal lesions, or any other sign of a hypersensitivity reaction. Signs of a severe adverse reaction, such as trouble breathing, chest pain, weakness in one part of the body, or swelling of the face or throat, warrant immediate emergency medical attention.

---

Q: Is Celecoxib Pentafarma appropriate for use by elderly patients?

Official information indicates that the plasma concentration of the medicine is generally higher in elderly individuals (age 65 and older). Particular caution is warranted for elderly patients, especially for older adults with low body weight.

---

Q: Can patients with pre-existing high blood pressure use Celecoxib Pentafarma?

Regulatory documents state that this medicine may cause new hypertension (high blood pressure) or worsen pre-existing hypertension. Blood pressure control is noted as a requirement before treatment initiation, and monitoring of blood pressure is warranted during therapy.

---

Q: Is it safe to take Celecoxib Pentafarma at the same time as low-dose aspirin?

The medicine does not substitute for the cardiovascular protective effects of low-dose aspirin. Taking it concurrently with aspirin, particularly at antiplatelet doses, may increase the risk of serious gastrointestinal events (like bleeding), and co-administration is subject to the review and management of a healthcare provider.

---

Q: What does the available research evidence say about the effectiveness of Celecoxib Pentafarma?

Clinical studies summarized in official labeling show that the medicine provides significant reduction in joint pain and inflammation for approved uses such as osteoarthritis and rheumatoid arthritis. Pain relief is typically achieved within 24 to 48 hours after beginning a regular dose.

---

Q: Are there different strengths of Celecoxib Pentafarma capsules available?

Official labeling for celecoxib typically lists commercially available capsule strengths. The common capsule strengths are 100 mg and 200 mg.

---

Q: What are the signs of a severe allergic reaction that requires immediate attention?

Signs of a severe allergic reaction (anaphylaxis) that warrant immediate emergency medical attention include swelling of the face or throat, shortness of breath, chest pain, and sudden weakness in one part of the body.

---

Q: Does Celecoxib Pentafarma work for all types of inflammation?

The medicine is approved only for the symptomatic relief of specific inflammatory conditions, such as osteoarthritis and rheumatoid arthritis, as well as for acute pain. It is not indicated for all types of inflammation.

---

Q: Is it okay to take Celecoxib Pentafarma if I have a history of stomach ulcers that have already healed?

Patients who have a prior history of stomach ulcers or gastrointestinal bleeding are considered to be at an increased risk of serious gastrointestinal complications. The official product information indicates that caution is warranted for this population.

---

Q: Is it true that Celecoxib Pentafarma is thought to be easier on the stomach than older pain medicines?

The mechanism of action for this medicine involves selective COX-2 inhibition, which means it largely spares the COX-1 enzyme. The COX-1 enzyme plays a role in maintaining the protective stomach lining.

---

Q: What are the known concerns about using Celecoxib Pentafarma in young children?

Use in children is strictly restricted to the management of Juvenile Rheumatoid Arthritis (JRA) in patients 2 years of age and older. Safety and efficacy are not established for children younger than two years of age or for general use in non-JRA conditions.

---

Q: Are there any food or diet restrictions while taking Celecoxib Pentafarma?

Official labeling states that there are no specific food or diet restrictions listed for this medicine. It can generally be taken with or without food, although consuming it with a high-fat meal can delay the time it takes to reach peak levels in the body.

---

Q: What information is available regarding the use of Celecoxib Pentafarma while breastfeeding?

Limited published data indicates that the medicine is present at low levels in breast milk. Official documents advise that caution is warranted when considering administration to a nursing woman.

---

Q: Is there a known interaction risk between Celecoxib Pentafarma and antidepressants?

The medicine can inhibit the CYP2D6 enzyme system, which is used by the body to process many antidepressants. This inhibition may increase the plasma levels of certain co-administered antidepressants. This interaction is a factor requiring caution and management by a healthcare provider.

---

Q: What risks are associated with drinking alcohol while taking Celecoxib Pentafarma?

Official documents advise caution regarding alcohol consumption while taking this medicine. Alcohol use is considered a risk factor for developing serious gastrointestinal complications, such as ulcers or bleeding, in patients taking this class of medication.

---

Q: What are the signs of a potential overdose with Celecoxib Pentafarma?

Symptoms reported in cases of overdose include drowsiness, lethargy, nausea, vomiting, and epigastric pain (upper abdominal pain). Signs of a severe overdose may include continuing thirst, trouble breathing, dizziness, or a sudden decrease in the amount of urine.

---

Q: Is there any information about Celecoxib Pentafarma causing problems with fertility?

NSAIDs, including this medicine, may be associated with a reversible delay in ovulation and may impair female fertility. Official guidance indicates that healthcare providers may consider discontinuing the medicine in women who are having difficulties conceiving.

---

Q: Can Celecoxib Pentafarma affect the skin's sensitivity to sun exposure?

The medicine is associated with a risk of serious skin reactions. Regulatory documents advise that discontinuation is warranted immediately if a rash develops.

---

Q: What is the duration of action for Celecoxib Pentafarma in the body?

The effective half-life of the active ingredient is approximately 11 hours. Following regular oral dosing, steady state plasma levels—where the amount of medicine entering the body equals the amount leaving—are typically reached within five days.

---

Q: Are there any known interactions between Celecoxib Pentafarma and herbal supplements?

The official safety information notes that patients should provide their healthcare provider with a complete list of all medications and herbal supplements, as herbal supplements may increase the risk for serious side effects.

How to Store and Dispose of Celecoxib Pentafarma

Celecoxib capsules must be stored at Controlled Room Temperature, defined as 20 C to 25 C, with a maximum limit not exceeding 30 C. The medicine must be kept in its original container, which should be tightly closed to protect the contents from excess heat and moisture; freezing is strictly prohibited. It is required to store the product out of the sight and reach of children.

Stability and Disposal Rules

Unused or expired Celecoxib must be disposed of according to official regulatory channels; the product must not be thrown in the garbage or poured down a drain.

Preparation	Stability Condition
Contents mixed with applesauce, rice gruel, or yogurt	Stable for up to 6 hours when refrigerated (2 C to 8 C)
Contents mixed with mashed banana	Must be ingested immediately (not stored)